These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15613062)

  • 61. Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients?
    Engeli S; Jordan J
    Curr Hypertens Rep; 2013 Oct; 15(5):470-4. PubMed ID: 23933756
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Renoprotecion With Metabolic Syndrome: the Possibility of Receptor Agonist Imidazoline Moxonidine].
    Ostroumova OD; Zykova AA
    Kardiologiia; 2016 Oct; 56(10):72-79. PubMed ID: 28290898
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [The use of moxonidine in the treatment of arterial hypertension].
    Vachek J
    Vnitr Lek; 2021; 67(3):170-172. PubMed ID: 34171957
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives.
    Hansson L
    Blood Press Suppl; 1998; 3():20-2. PubMed ID: 10321450
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of hypertension with clonidine.
    MacDougall AI; Addis GJ; MacKay N; Dymock IW; Turpie AG; Ballingall DL; MacLennan WJ; Whiting B; MacArthur JG
    Br Med J; 1970 Aug; 3(5720):440-2. PubMed ID: 5454324
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacotherapeutic strategies for treating hypertension in patients with obesity.
    Carnagarin R; Matthews V; Gregory C; Schlaich MP
    Expert Opin Pharmacother; 2018 May; 19(7):643-651. PubMed ID: 29600880
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Moxonidine is advantageous for hypertensive type 2 diabetic patients. Therapy of hypertension also lowers HbA1c].
    MMW Fortschr Med; 2003 Jan; 145(1-2):57. PubMed ID: 12638449
    [No Abstract]   [Full Text] [Related]  

  • 68. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study.
    Chazova I; Schlaich MP
    Int J Hypertens; 2013; 2013():541689. PubMed ID: 23533713
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hypertension and non-insulin dependent diabetes.
    Yudkin JS
    BMJ; 1991 Sep; 303(6805):730-2. PubMed ID: 1796956
    [No Abstract]   [Full Text] [Related]  

  • 70. [Prospects of the impact of antihypertensive therapy on the pathogenetic mechanisms of insulin resistance].
    Ametov AS; Demidova TY; Smagina LV
    Probl Endokrinol (Mosk); 2005 Feb; 51(1):34-39. PubMed ID: 31627535
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Advances in the treatment of hypertension.
    Pickering TG
    JAMA; 1999 Jan; 281(2):114-6. PubMed ID: 9917098
    [No Abstract]   [Full Text] [Related]  

  • 72. A Prospective Real World Experience of Moxonidine Use in Indian Hypertensive Patients-Prescription beyond Current Guidelines.
    Sagarad SV; Biradar-Kerure S; Mr R; Kumar S C; Reddy SS
    J Clin Diagn Res; 2013 Oct; 7(10):2213-5. PubMed ID: 24298479
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The role of moxonidine, a second generation centrally acting antihypertensive agent as antihypertensive therapy in the obese.
    Karlafti E; Hatzitolios A; Savopoulos Ch
    Hippokratia; 2014 Apr; 18(2):189. PubMed ID: 25336891
    [No Abstract]   [Full Text] [Related]  

  • 74. Moxonidine: a review of its use in essential hypertension.
    Fenton C; Keating GM; Lyseng-Williamson KA
    Drugs; 2006; 66(4):477-96. PubMed ID: 16597164
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
    Abellán J; Leal M; Hernández-Menárguez F; García-Galbis JA; Martínez-Pastor A; de Vinuesa SG; Luño J
    Kidney Int Suppl; 2005 Jan; (93):S20-4. PubMed ID: 15613062
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety and efficacy of moxonidine in mild to moderate hypertension.
    Jain S; Malhotra P; Kumari S; Varma S
    J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.